Biomarker predicts KRASG12C inhibitor success in lung cancer treatment
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...
FierceBiotech3 天
Cullinan plans approval application for lung cancer drug this year based on phase 2 win
Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...
Targeted Oncology12 天
Kim Evaluates New Regimens for EGFR+ Lung Cancer
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.
Targeted Oncology13 天
EGFR+ Lung Cancer
The FDA granted priority review to datopotamab deruxtecan in advanced EGFR-mutated NSCLC after prior therapies, with a decision expected by July 12, 2025. The FDA granted priority review to ...
来自MSN12 天
Daily pill for lung cancer to be made routinely available on the NHS
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery when taken ...
pharmaphorum3 天
Tagrisso on target to be EGFR+ lung cancer standard
New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer. AstraZeneca has been ...
GlobalData on MSN10 天
AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and Imfinzi
Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.
来自MSN11 天
Cancer breakthrough: Daily pill which can DOUBLE survival time of lung cancer patients to ...
A breakthrough daily pill which doubles the survival time for certain lung cancer patients will now be routinely available on ...